Cell-Free DNA Methylation Profiling
What Is Cell-Free DNA Methylation Profiling?
Cell-free DNA (cfDNA) methylation profiling is an advanced approach for analyzing the epigenetic signatures of DNA fragments circulating in the bloodstream. Unlike mutation-based ctDNA analysis, this method interrogates DNA methylation patterns, which are tissue- and cancer-type specific, providing powerful biomarkers for disease detection, classification, and monitoring.
Methylation marks, primarily 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), regulate gene expression and reflect the cell of origin of cfDNA fragments. By mapping these methylation patterns using next-generation sequencing (NGS), researchers can:
-
Identify the tissue source of cfDNA,
-
Detect cancer and other diseases earlier,
-
Monitor treatment responses and disease progression.
AUGenomics utilizes ultra-sensitive methylation sequencing workflows (including EM-Seq for enzymatic conversion) to preserve DNA integrity, maximize CpG coverage, and enable accurate profiling from the low quantities of cfDNA typically found in plasma samples.
Advantages of cfDNA Methylation Profiling
01
Tissue-of-Origin Insights: Methylation patterns reveal the cellular sources of cfDNA fragments.
02
Non-Invasive Detection: Uses a simple blood draw, eliminating the need for invasive tissue biopsies.
03
Ultra-Low Input Compatibility: Works with as little as 10 ng cfDNA, ideal for early-stage or minimal disease samples.
04
High CpG Coverage: Detects more CpG sites at greater depth than traditional bisulfite methods.
05
Accurate Methylation Quantification: Differentiates 5mC and 5hmC with high specificity using enzymatic conversion.
06
Minimal DNA Damage: Preserves fragment integrity for improved mapping and library complexity.
07
Flexible Assay Options: Supports whole-genome or targeted methylation profiling.
08
Advanced Bioinformatics: Provides methylation maps, tissue-of-origin deconvolution, and differential methylation analysis.
09
Clinical & Translational Relevance: Supports biomarker discovery, cancer diagnostics research, and liquid biopsy studies.
10
apid Turnaround: Standard delivery in 2–3 weeks, with expedited options available.
cfDNA methylation profiling is revolutionizing liquid biopsy research and early detection of disease. Common applications include:
-
Early Cancer Detection: Identifying cancer-specific methylation patterns before clinical symptoms arise.
-
Tumor Classification: Distinguishing between cancer types based on unique methylation signatures.
-
Monitoring Disease Progression: Tracking methylation dynamics during treatment or remission.
-
Minimal Residual Disease (MRD) Assessment: Detecting residual tumor cells through sensitive methylation biomarkers.
-
Non-Cancer Applications: Investigating methylation patterns in cfDNA for cardiovascular, neurological, and inflammatory diseases.
-
Biomarker Discovery: Identifying methylation signatures for diagnostic or prognostic use.
-
Liquid Biopsy Research: Advancing epigenetic diagnostics using cfDNA from blood or other body fluids.
What is cfDNA Methylation Profiling Used For?
cfDNA Methylation Profiling with AUGenomics
Sample Submission
Minimum 10–20 ng of high-quality cfDNA extracted from plasma or other biofluids. We recommend EDTA or Streck tubes for blood collection. Samples must be shipped overnight on dry ice.
Please refer to our Shipping Guidelines for project-specific guidance.
Turnaround Time
Typical turnaround for cfDNA methylation profiling is 12–15 business days from sample receipt. Expedited options are available depending on project scope and sequencing depth.
Frequently Asked Questions (FAQs)
Q: Why use methylation profiling over regular cfDNA sequencing?
A: Methylation offers insights into gene regulation and tissue origin, while regular cfDNA sequencing captures genetic alterations. Both provide complementary information.
Q: What types of diseases can be studied using this method?
A: cfDNA methylation is widely used in oncology, but also applies to prenatal testing, autoimmune disease, and neurodegenerative conditions.
Q: How much plasma should I collect?
A: We recommend at least 4–5 mL of plasma to yield sufficient cfDNA for methylation analysis.
Q: How does cfDNA methylation profiling differ from ctDNA mutation analysis?
A: While ctDNA mutation assays detect specific genetic alterations, methylation profiling captures epigenetic patterns that reflect the tissue of origin and regulatory changes not visible through mutation analysis alone.
Q: What sequencing method do you use?
A: AUGenomics uses enzymatic methylation sequencing (EM-Seq) and other optimized workflows to maximize CpG coverage and minimize DNA damage.
Q: What sample types are compatible?
A: Plasma is the preferred sample for cfDNA extraction. We provide guidelines for collection, stabilization, and shipment.
Q: How much DNA input is required?
A: As little as 10 ng of cfDNA is sufficient for high-quality profiling using our workflows.
Q: Can you profile 5hmC as well as 5mC?
A: Yes. Our enzymatic workflows can accurately distinguish between 5mC and 5hmC modifications.
Q: Is this service intended for clinical diagnostics?
A: Our cfDNA methylation profiling is currently offered for research use only (RUO) but provides data highly relevant to translational and biomarker studies.
Got more questions? Contact our team and get a free consultation anytime. info@augenomics.com
Glossary of Terms
-
cfDNA: Short fragments of DNA freely circulating in biofluids
-
Methylation profiling: Mapping of methyl groups on DNA to study gene regulation
-
Epigenetics: Study of heritable changes in gene expression not caused by changes in DNA sequence
-
Liquid biopsy: A non-invasive test that detects cancer or other conditions using biofluids
